Literature DB >> 28108828

A Novel Biomarker-Based Preoperative Prognostic Grading System for Predicting Survival After Surgery for Intrahepatic Cholangiocarcinoma.

Tomoaki Yoh1, Satoru Seo2, Etsuro Hatano3, Kojiro Taura1, Hiroaki Fuji1, Yoshinobu Ikeno1, Yukihiro Okuda1, Kentaro Yasuchika1, Toshimi Kaido1, Hideaki Okajima1, Shinji Uemoto1.   

Abstract

BACKGROUND: Although treatment strategies for intrahepatic cholangiocarcinoma (ICC) are shifting towards multidisciplinary approaches, preoperative radiographic methods for identifying patients requiring further therapy are unclear. This study was designed to establish a prognostic grading system using preoperatively available objective biomarkers.
METHODS: A novel preoperative prognostic grading system for predicting survival after surgery for ICC was developed from multivariate analysis of 134 ICC patients who underwent surgery between 1996 and 2015 using preoperatively available biomarkers.
RESULTS: The median overall survival time and 3- and 5 year survival rates were 33.3 months, 48, and 38%, respectively. Of the preoperative biomarkers, the neutrophil-to-lymphocyte ratio (≥5), and C-reactive protein (≥5 mg/L) and carbohydrate antigen 19-9 (≥500 IU/mL) levels were independently associated with poor overall survival. Based on the presence of these factors, the preoperative prognostic grades were defined as follows: grade 1, no factor; grade 2, one factor; and grade 3, two or three factors. The median overall survival time and 3- and 5 year survival rates of patients with grade 1 (70.3 months, 66, and 53%, respectively) were higher than those of patients with grade 2 (23.4 months, 37, and 30%, respectively; P = 0.004) and grade 3 (8.8 months, 5% both; 2 vs. 3, P < 0.001). Multivariable analysis revealed that the preoperative prognostic grading system independently predicted survival after adjusting for known prognostic factors.
CONCLUSIONS: A novel biomarker-based preoperative prognostic grading system for ICC significantly stratifies survival after surgery and may identify patients requiring further treatment.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28108828     DOI: 10.1245/s10434-016-5708-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  13 in total

1.  A Low Neutrophil to Lymphocyte Ratio Before Preoperative Chemotherapy Predicts Good Outcomes After the Resection of Colorectal Liver Metastases.

Authors:  Rui Mao; Jian-Jun Zhao; Xin-Yu Bi; Ye-Fan Zhang; Zhi-Yu Li; Zhen Huang; Jian-Guo Zhou; Hong Zhao; Jian-Qiang Cai
Journal:  J Gastrointest Surg       Date:  2018-07-31       Impact factor: 3.452

2.  [Intrahepatic cholangiocarcinoma : Results after 84 resections].

Authors:  H P Neeff; P A Holzner; M Menzel; P Bronsert; A Klock; S A Lang; S Fichtner-Feigl; U T Hopt; F Makowiec
Journal:  Chirurg       Date:  2018-05       Impact factor: 0.955

Review 3.  Systematic Review and Meta-Analysis of Prognostic Factors for Early Recurrence in Intrahepatic Cholangiocarcinoma After Curative-Intent Resection.

Authors:  Woo Jin Choi; Phil J Williams; Marco P A W Claasen; Tommy Ivanics; Marina Englesakis; Steven Gallinger; Bettina Hansen; Gonzalo Sapisochin
Journal:  Ann Surg Oncol       Date:  2022-02-18       Impact factor: 5.344

4.  Impact of Preoperative CEA Uptrend on Survival Outcomes in Patients with Colorectal Liver Metastasis After Hepatectomy.

Authors:  Yutaro Hori; Satoru Seo; Tomoaki Yoh; Kentaro Ueno; Koshiro Morino; Rei Toda; Takahiro Nishio; Yukinori Koyama; Ken Fukumitsu; Takamichi Ishii; Koichiro Hata; Toshihiko Masui; Kojiro Taura; Etsuro Hatano
Journal:  Ann Surg Oncol       Date:  2022-06-12       Impact factor: 4.339

5.  The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma.

Authors:  Amika Moro; Rittal Mehta; Kota Sahara; Diamantis I Tsilimigras; Anghela Z Paredes; Ayesha Farooq; J Madison Hyer; Itaru Endo; Feng Shen; Alfredo Guglielmi; Luca Aldrighetti; Matthew Weiss; Todd W Bauer; Sorin Alexandrescu; George A Poultsides; Shishir K Maithel; Hugo P Marques; Guillaume Martel; Carlo Pulitano; Olivier Soubrane; Bas G Koerkamp; Kazunari Sasaki; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2020-03-20       Impact factor: 5.344

6.  MRI features predict microvascular invasion in intrahepatic cholangiocarcinoma.

Authors:  Xijuan Ma; Liheng Liu; Jun Fang; Shengxiang Rao; Lulu Lv; Mengsu Zeng; Yibing Shi; Chun Yang
Journal:  Cancer Imaging       Date:  2020-06-23       Impact factor: 3.909

Review 7.  Prognostic Significance of Platelet-to-Lymphocyte Ratio in Cholangiocarcinoma: A Meta-Analysis.

Authors:  Gang Hu; Qin Liu; Jian-Ying Ma; Cheng-Yuan Liu
Journal:  Biomed Res Int       Date:  2018-11-14       Impact factor: 3.411

8.  Systemic inflammation score predicts survival in patients with intrahepatic cholangiocarcinoma undergoing curative resection.

Authors:  Yong Zhang; Shi-Ming Shi; Hua Yang; Liu-Xiao Yang; Zheng Wang; Xue-Dong Li; Dan Yin; Ying-Hong Shi; Ya Cao; Zhi Dai; Jian Zhou; Qing Chen
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

9.  The prognostic value of sarcopenia combined with preoperative fibrinogen-albumin ratio in patients with intrahepatic cholangiocarcinoma after surgery: A multicenter, prospective study.

Authors:  Haitao Yu; Mingxun Wang; Yi Wang; Jinhuan Yang; Liming Deng; Wenming Bao; Bangjie He; Zixia Lin; Ziyan Chen; Kaiyu Chen; Baofu Zhang; Fangting Liu; Zhengping Yu; Longyun Ye; Bin Jin; Gang Chen
Journal:  Cancer Med       Date:  2021-06-08       Impact factor: 4.452

10.  Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis.

Authors:  Yoshinobu Ikeno; Satoru Seo; Keiko Iwaisako; Tomoaki Yoh; Yuji Nakamoto; Hiroaki Fuji; Kojiro Taura; Hideaki Okajima; Toshimi Kaido; Shimon Sakaguchi; Shinji Uemoto
Journal:  J Transl Med       Date:  2018-04-11       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.